摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-methylimidazo[1,5-a]pyrazine | 864870-71-3

中文名称
——
中文别名
——
英文名称
6-methylimidazo[1,5-a]pyrazine
英文别名
6-Methylimidazo[1,5-A]pyrazine
6-methylimidazo[1,5-a]pyrazine化学式
CAS
864870-71-3
化学式
C7H7N3
mdl
——
分子量
133.153
InChiKey
PCLBLJPASXWVQL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.24±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    30.2
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    6-methylimidazo[1,5-a]pyrazine 、 prop-2-enyl (4S,5R,6S)-3-(diphenoxyphosphoryloxymethyl)-4-methyl-7-oxo-6-[(1R)-1-prop-2-enoxycarbonyloxyethyl]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate 在 四(三苯基膦)钯 sodium iodide 、 2-乙基-己酸稀土盐potassium 2-ethylhexanoate三苯基膦 作用下, 以 N,N-二甲基甲酰胺二氯甲烷 为溶剂, 生成
    参考文献:
    名称:
    CP0569, A New Broad-Spectrum Injectable Carbapenem. Part 1: Synthesis and Structure–Activity Relationships
    摘要:
    A series of 10-methylcarbapenems bearing an (imidazo[5,1-b]thiazolium-6-yl)methyl moiety, a 5,5-fused heterobicycle, at the C-2 position was synthesized and evaluated for in vitro antibacterial activities. CP0569 (1r) and its analogues showed potent antibacterial activities against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), and Gram-negative bacteria, including Pseudomonas aeruginosa. Moreover, CP0569 (1r) exhibited stronger antibacterial activity against MRSA and higher resistance to renal dehydropeptidase-1 (DHP-1) than any currently marketed carbapenems, that is, imipenem (IPM), panipenem (PAPM), and meropenem (MEPM). (C) 2003 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/s0968-0896(03)00304-3
  • 作为产物:
    描述:
    2-formylaminomethyl-5-methylpyrazine三氯氧磷 作用下, 反应 1.0h, 以67%的产率得到6-methylimidazo[1,5-a]pyrazine
    参考文献:
    名称:
    CP0569, A New Broad-Spectrum Injectable Carbapenem. Part 1: Synthesis and Structure–Activity Relationships
    摘要:
    A series of 10-methylcarbapenems bearing an (imidazo[5,1-b]thiazolium-6-yl)methyl moiety, a 5,5-fused heterobicycle, at the C-2 position was synthesized and evaluated for in vitro antibacterial activities. CP0569 (1r) and its analogues showed potent antibacterial activities against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), and Gram-negative bacteria, including Pseudomonas aeruginosa. Moreover, CP0569 (1r) exhibited stronger antibacterial activity against MRSA and higher resistance to renal dehydropeptidase-1 (DHP-1) than any currently marketed carbapenems, that is, imipenem (IPM), panipenem (PAPM), and meropenem (MEPM). (C) 2003 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/s0968-0896(03)00304-3
点击查看最新优质反应信息

文献信息

  • SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
    申请人:BlinkBio, Inc.
    公开号:US20170202970A1
    公开(公告)日:2017-07-20
    Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.
    本文描述了基于硅的共轭物,能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心,一个或多个可选的催化基团,一个定位基团,允许共轭物在靶细胞或组织内积累,一个或多个有效载荷基团(例如,治疗剂或成像剂),以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
  • NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN, ETC
    申请人:Rhizen Pharmaceuticals SA
    公开号:US20150057309A1
    公开(公告)日:2015-02-26
    The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.
    本发明提供了作为c-Met蛋白激酶调节剂有用的化合物,以及制备它们的方法,含有它们的药物组合物,以及使用它们进行治疗、预防和/或改善c-Met激酶介导的疾病或疾病的方法。
  • NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND
    申请人:Iijima Toru
    公开号:US20140011807A1
    公开(公告)日:2014-01-09
    The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein R 1 is a cycloalkyl group and the like, R 22 is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is —O— and the like, and R 3 to R 6 are the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.
    本发明提供了一种含氮饱和杂环化合物,化学式为[I],其中R1是环烷基等,R2是可选取代的芳基等,R是低碳基等,T是羰基,Z是- O-等,R3至R6相同或不同,是氢原子等;或药学上可接受的盐,用作肾素抑制剂。
  • NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED-3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES
    申请人:Rhizen Pharmaceuticals SA
    公开号:US20180072721A1
    公开(公告)日:2018-03-15
    The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.
  • US9815831B2
    申请人:——
    公开号:US9815831B2
    公开(公告)日:2017-11-14
查看更多

同类化合物

顺式-3-(8-氨基-1-溴咪唑并[1,5-a]吡嗪-3-基)-1-甲基环丁醇 咪唑并[1,5-a]吡嗪-8-胺 咪唑并[1,5-a]吡嗪-8(7H)-硫酮 N-(2,6-二甲基苯基)-5-(4-甲氧基苯基)咪唑并[1,5-a]吡嗪-8-胺 N-(2,6-二甲基苯基)-5-(3-甲氧基苯基)咪唑并[1,5-a]吡嗪-8-胺 8-氯咪唑并[1,5-a]吡嗪 8-氯咪唑并[1,5-A]吡嗪-1-甲酸乙酯 8-氯-3-环丁基-1-碘-咪唑并[1,5-a]吡嗪 8-氯-3-异丙基咪唑并[1,5-A]吡嗪 5H,10H-二咪唑并[1,5-a:1, 5-d] 吡嗪-5,10-二酮 5-溴-7-(4-甲氧基苄基)咪唑并[1,5-a]吡嗪-8-(7H)-酮 5-(4-甲氧基苯基)-7H-咪唑并[1,5-a]吡嗪-8-酮 5,10-二氧代-5H,10H-二咪唑并[1,5-a:1',5'-d]吡嗪-1,6-二甲酸 3-甲基咪唑并[1,5-a]吡嗪-8(7H)-硫酮 3-甲基咪唑并[1,5-A]吡嗪 3-环己基咪唑并[1,5-a]吡嗪 3-环丁基-1-碘-咪唑并[1,5-a]吡嗪-8-胺 3-(甲硫基)-1-硝基-咪唑并[1,5-a]吡嗪 3-(甲氧基甲基)-咪唑并[1,5-a]吡嗪 3-(叔丁基)-8-氯咪唑并[1,5-a]吡嗪 3-(叔丁基)-8-氯-1-碘咪唑并[1,5-a]吡嗪 3-(三氟甲基)咪唑并[1,5-a]吡嗪 3-(8-BROMO-1-CHLOROH-PYRROLO[1,2-A]PYRAZIN-6-YL)CYCLOBUTANONE无结构图 3-(1-CHLOROH-PYRROLO[1,2-A]PYRAZIN-6-YL)CYCLOBUTANONE无结构图 1-碘-3-叔丁基咪唑并[1,5-a]吡嗪-8-胺 1-溴-3-甲基-咪唑并[1,5-a]吡嗪 1-溴-3-(四氢-2H-吡喃-4-基)咪唑并[1,5-a]吡嗪-8-胺 (S)-1-bromo-8-methyl-3-(pyrrolidin-3-yl)imidazo[1,5-a]pyrazine hydrochloride tert-butyl (4-(1-bromo-3-isopropylimidazo[1,5-a]pyrazin-5-yl)cyclohex-3-en-1-yl)(methyl)carbamate 8-chloro-5-phenylimidazo[1,5-a]pyrazine 3-(6-(1,4-diazepan-1-yl)pyridin-2-yl)-6-(6-methylpyrazin-2-yl)imidazo[1,5-a]pyrazine N-(2,6-dimethylphenyl)-5-{3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}imidazo[1,5-a]pyrazin-8-amine 3-bromo-8-chloroimidazo[1,5-a]pyrazine N3-(2,4-Dichloro-phenyl)-N8,N8-diethyl-1-methyl-imidazo[1,5-a]pyrazine-3,8-diamine 7-(3-fluorobenzyl)-6-methyl-3(S)-(3-methyltetrahydrofuran-3-yl)imidazo[1,5-a]pyrazin-8(7H)-one E-1-(6,7-dimethyl-8-oxo-7,8-dihydroimidazo[1,5-a]pyrazin-1-yl)-2-ethyl-3-phenylisothiourea 7-(3-chloro-4-methoxybenzyl)-6-methyl-3-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]pyrazin-8(7H)-one 8-chloro-3-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]pyrazine 3-cyclobutyl-1-(phenylethynyl)imidazo[1,5-a]pyrazin-8-amine ethyl 1-bromoimidazo[1,5-a]pyrazine-3-carboxylate Imidazo[1,5-a]pyrazine-3-carboxylic acid,1-(4-morpholinyl)-,ethyl ester Imidazo[1,5-a]pyrazine-1-methanol,8-chloro- methyl 3-methylimidazo[1,5-a]pyrazine-1-carboxylate Imidazo[1,5-a]pyrazine-1-methanol,8-chloro-6-methyl- Ethyl 8-Hydroxyimidazo[1,5-a]pyrazine-1-carboxylate Imidazo[1,5-a]pyrazine,8-chloro-6-phenyl- (1S,6R,8aS)-6-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-1-methyltetrahydro-1H-oxazolo[3,4-a]pyridin-3(5H)-one (1-bromo-8-methylimidazo[1,5-a]pyrazin-3-yl)methanol 3-((1H-imidazol-1-yl)methyl)-1-bromo-8-methylimidazo[1,5-a]pyrazine 8-methyl-3-(piperidin-4-yl)imidazo[1,5-a]pyrazine